 MALVERN, Pa., Feb. 08, 2021 GLOBE NEWSWIRE -- Baudax Bio, Inc. NASDAQ:BXRX, a pharmaceutical company focused on therapeutics for acute care settings, Baudax Bio or the Company today announced that it has entered into a definitive agreement with institutional and accredited investors for the purchase and sale of an aggregate of 11,000,000 shares of common stock at a purchase price of 1.60 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 10, 2021, subject to the satisfaction of customary closing conditions. 